We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Proteomics of Alveolar Macrophages

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00806091
First Posted: December 10, 2008
Last Update Posted: December 10, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ohio State University
  Purpose
The purpose of this study is to obtain young white blood cells (monocytes) from the investigators donated blood for research into how these cells change into large, mature white blood cells (macrophages) and how smoking causes Chronic Obstructive Pulmonary Disease (COPD).

Condition
COPD

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Functional Proteomics of Alveolar Macrophages

Further study details as provided by Ohio State University:

Primary Outcome Measures:
  • to define AM's pathogenic pathways underlying the development of COPD [ Time Frame: end of study ]

Secondary Outcome Measures:
  • to determine protein polymorphism(s) that impact genetic susceptibility to COPD [ Time Frame: end of study ]

Biospecimen Retention:   Samples With DNA
blood BAL fluid breathe condensation saliva

Enrollment: 72
Study Start Date: July 2004
Study Completion Date: December 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
COPD subjects
healthy subjects

Detailed Description:
Our research goal is to identify new targets and strategies to help care for patients with Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic airway inflammatory disorder characterized by a progressive loss of pulmonary function. Mononuclear phagocytes are known to be critically involved in both repair/remodeling and destructive events in COPD. Although smoking is the chief environmental risk factor for COPD, the molecular details responsible for the genesis and progression of smoking-mediated COPD require further investigation. In searching for new knowledge and research strategies for this challenging topic, we have made substantial progress in mononuclear phagocyte proteomics and laid the groundwork for this translational research of COPD.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
smokers with and without COPD, general population
Criteria

Inclusion Criteria:

  • COPD, smoker
  • COPD, non smoker

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00806091


Locations
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Ohio State University
Investigators
Principal Investigator: Haifeng Wu, MD Ohio State University
  More Information

Responsible Party: Haifeng Wu, The Ohio State University
ClinicalTrials.gov Identifier: NCT00806091     History of Changes
Other Study ID Numbers: 2004H0102
First Submitted: December 9, 2008
First Posted: December 10, 2008
Last Update Posted: December 10, 2008
Last Verified: December 2008

Keywords provided by Ohio State University:
AM proteomes will be compared between smokers with and without COPD